Jun 25, 2026 · 19 min · 9 segments
This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on…
John BazarHost
in a nature journal for what was described as a randomized controlled trial of timing of immune checkpoint or immunotherapy in patients, and this was in China.
That has been retracted because turns out it was looking like it was really a retrospective study.
that they said was a randomized prospective study, and it was caught based on some somewhat obvious errors that, to be honest, I missed when I didn't review the study as in-depth.
There is quite a bit of observational data that may be the timing of when you give immunotherapy early in the morning that it might work better.
This was a prospective study that added the most evidence to that, but it turns out it didn't add a whole lot.
in a nature journal for what was described as a randomized controlled trial of timing of immune checkpoint or immunotherapy in patients, and this was in China.
That has been retracted because turns out it was looking like it was really a retrospective study.
that they said was a randomized prospective study, and it was caught based on some somewhat obvious errors that, to be honest, I missed when I didn't review the study as in-depth.
There is quite a bit of observational data that may be the timing of when you give immunotherapy early in the morning that it might work better.
This was a prospective study that added the most evidence to that, but it turns out it didn't add a whole lot.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
